Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model

Transplantation

Volumn 81, Issue 12, 2006, Pages 1700-1707

  Bellido Reyes, Yury A ^a   Akamatsu, Hideki ^a   Kojima, Katsuo ^a   Arai, Hirokuni ^a   Tanaka, Hiroyuki ^a   Sunamori, Makoto ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Ischemia reperfusion; Lung transplantation; Phospholipase A2; Rat

Indexed keywords

ARACHIDONIC ACID DERIVATIVE; ARACHIDONYL TRIFLUOROMETHYLKETONE; LEUKOTRIENE; MYELOPEROXIDASE; PHOSPHOLIPASE A2; SODIUM CHLORIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOXANE; UNCLASSIFIED DRUG; ARACHIDONYLTRIFLUOROMETHANE; CALCIUM INDEPENDENT PHOSPHOLIPASE A2; CALCIUM-INDEPENDENT PHOSPHOLIPASE A2; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; ICOSANOID; PHOSPHOLIPASE A; PHOSPHOLIPASE A2 IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ISCHEMIA; LUNG ALVEOLUS MACROPHAGE; LUNG EDEMA; LUNG GAS EXCHANGE; LUNG INJURY; LUNG ISCHEMIA; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; NEUTROPHIL; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; LUNG; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; ARACHIDONIC ACIDS; DISEASE MODELS, ANIMAL; EICOSANOIDS; LUNG; LUNG TRANSPLANTATION; MALE; NEUTROPHILS; PHOSPHOLIPASES A; PHOSPHORYLATION; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; REPERFUSION INJURY;

EID: 33745458476     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226065.82066.21     Document Type: Article

References (44)

1. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report-2004. J Heart Lung Transplant 2004; 23: 804.
2. Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51.
3. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation 2003; 75: 1928.
4. Hidalgo MA, Shah KA, Fuller BJ, Green CJ. Cold ischemia-induced damage to vascular endothelium results in permeability alterations in transplanted lungs. J Thorac Cardiovasc Surg 1996; 112: 1027.
5. King RC, Binns OA, Rodriguez F, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69: 1681.
6. de Perrot M, Liu M, Waddel TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167: 490.
7. Toledo-Pereyra LH, Toledo AH, Walsh J, Lopez-Neblina F. Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant 2004; 2: 174.
8. Wittwer T, Grote M, Oppelt P, et al. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001; 20: 358.
9. Sunose Y, Takeyoshi I, Tsutsumi H, et al. Effect of a cyclooxygenase-2 inhibitor, FK3311, in a canine lung transplantation model. Ann Thorac Surg 2001; 72: 1165.
10. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30: S294.
11. Goggel R, Winoto-Morbach S, Vielhaber G, et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004; 10: 155.
12. Nagase T, Ishii S, Kume K, et al. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 1999; 104: 1071.
13. Zamora CA, Baron DA, Heffner JE. Thromboxane contributes to pulmonary hypertension in ischemia-reperfusion lung injury. J Appl Physiol 1993; 74: 224.
14. Wagner JG, Roth RA. Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol Rev 2000; 52: 349.
15. Chiang N, Gronert K, Clish CB, et al. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 1999; 104: 309.
16. Serhan CN. Preventing injury from within, using selective cPLA2 inhibitors. Nat Immunol 2000; 1: 13.
17. Arbibe L, Koumanov K, Vial D, et al. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest 1998; 102: 1152.
18. Beck GCh, Yard BA, Schulte J, et al. Secreted phospholipase A2 induce the expression of chemokines in microvascular endothelium. Biochem Biophys Res Commun 2003; 300: 731.
19. Chakraborti S. Phospholipase A(2) isoforms: a perspective. Cell Signal 2003; 15: 637.
20. Furue S, Mikawa K, Nishina K, et al. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med 2001; 29: 719.
21. Koike K, Yamamoto Y, Hori Y, Ono T. Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion. Ann Surg 2000; 232: 90.
22. Shen CY, Wang D, Chang ML, Hsu K. Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats. J Appl Physiol 1995; 78: 225.
23. Bonventre JV, Huang Z, Reza MT, et al. Reduced fertility and postischeamic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997; 390: 622.
24. Tabuchi S, Uozumi N, Ishii S, et al. Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury. Acta Neurochir Suppl 2003; 86: 169.
25. Nakos G, Kitsiouli E, Hatzidaki E, et al. Phospholipase A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33: 772.
26. Nagase T, Uozumi N, Ishii S, et al. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat Med 2002; 8: 480.
27. Meyer MC, Rastogi P, Beckett CS, McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 2005; 11: 1301.
28. Street IP, Lin HK, Laliberte F, et al. Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry 1993; 32: 5935.
29. Shimoyama T, Tabuchi N, Kojima K, et al. Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18-hours preservation. Eur J Cardiothorac Surg 2005; 28: 581.
30. Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985; 59: 1978.
31. Nagase T, Uozumi N, Aoki-Nagase T, et al. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2003; 284: L720.
32. Hausen B, Beuke M, Schroeder F, et al. In vivo measurement of lung preservation solution efficacy: comparison of LPD, UW, EC and low K+-EC following short and extended ischemia. Eur J Cardiothorac Surg 1997; 12: 771.
33. Nagase T, Uozumi N, Ishii S, et al. Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nat Immunol 2000; 1: 42.
34. Shimizu N, Kita T, Aoe M, et al. Changes in levels of arachidonic acid metabolites in blood and bronchoalveolar lavage fluid after warm ischemia-reperfusion of lung. Acta Med Okayama 1991; 45: 417.
35. Su M, Chi EY, Bishop MJ, Henderson WR Jr. Lung mast cells increase in number and degranulate during pulmonary artery occlusion/reperfusion injury in dogs. Am Rev Respir Dis 1993; 147: 448.
36. Corcoran PC, Wang Y, Katz NM, et al. Platelet activating factor antagonist enhances lung preservation in a canine model of single lung allotransplantation. J Thorac Cardiovasc Surg 1992; 104: 66.
37. Kawahara K, Tagawa T, Takahashi T, et al. The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung. Transplantation 1993; 55: 1438.
38. Shinohara H, Balboa MA, Johnson CA, et al. Regulation of delayed prostaglandin production in activated P388D1 macrophages by group IV cytosolic and group V secretory phospholipase A2s. J Biol Chem 1999; 274: 12263.
39. Balsinde J, Balboa MA, Dennis EA. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci USA 1998; 95: 7951.
40. Williams SD, Gottlieb RA. Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective. Biochem J 2002; 362: 23.
41. Fiser SM, Tribble CG, Long SM, et al. Lung transplant reperfusion injury involves pulmonary macrophages and circulating leukocytes in a biphasic response. J Thorac Cardiovasc Surg 2001; 121: 1069.
42. Naidu BV, Krishnadasan B, Farivar AS, et al. Early activation of the alveolar macrophages is critical to the development of lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2003; 126: 200.
43. Lu YT, Hellewell PG, Evans TW. Ischemia-reperfusion lung injury: contribution of ischemia, neutrophils, and hydrostatic pressure. Am J Physiol 1997; 273: L46.
44. Abraham E, Naum C, Bandi V, et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31: 718.